Kaposi’s sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy | Zendy

D’Addona Matteo | Zendy; Pezzullo Luca | Zendy; Giudice Valentina | Zendy; Serio Bianca | Zendy; Baldi Carlo | Zendy; Zeppa Pio | Zendy; Selleri Carmine | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Kaposi’s sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy

Author(s) -

D’Addona Matteo,

Pezzullo Luca,

Giudice Valentina,

Serio Bianca,

Baldi Carlo,

Zeppa Pio,

Selleri Carmine

Publication year - 2022

Publication title -

clinical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.21

H-Index - 9

ISSN - 2050-0904

DOI - 10.1002/ccr3.5919

Subject(s) - medicine , myeloid leukemia , imatinib mesylate , sarcoma , imatinib , immunosuppression , myeloid sarcoma , tyrosine kinase inhibitor , dasatinib , leukemia , tyrosine kinase , cancer research , immunology , pathology , cancer , receptor

Kaposi's sarcoma is associated with immunosuppression and human herpesvirus 8 infection, while rarely described in myeloid malignancies. Here, we illustrate a rare case of chronic myeloid leukemia treated with imatinib, a tyrosine kinase inhibitor, who developed a human herpesvirus 8‐related Kaposi's sarcoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research